Protara Therapeutics News and Activities

Protara Therapeutics is a company listed under the stock ticker TARA (US).

View the org chart displaying its 22 main executives

Most searched biographies at Protara Therapeutics

• Jesse Shefferman, Chief Executive Officer and Director
• Barry Flannelly, Director
• Jane Huang, Director

Popular executive movements at Protara Therapeutics

• John Mcrae has joined the company as Director, Clincal Operations  (posted on April 20 2026).

Create your alert
to follow the executive moves at Protara Therapeutics.

Protara Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Protara Therapeutics

• Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update | Protara Therapeutics, Inc.
• Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference | Protara Therapeutics, Inc.
• Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ | Protara Therapeutics, Inc.
• Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations | Protara Therapeutics, Inc.
• Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock – Protara Therapeutics, Inc.
• Press Releases – Protara Therapeutics, Inc.
• Press Releases – Protara Therapeutics, Inc.
• Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – Protara Therapeutics, Inc.
• Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations – Protara Therapeutics, Inc.
• Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors – Protara Therapeutics, Inc.
• View more press releases Close

Social media about Protara Therapeutics

• Protara Therapeutics on Wikipedia, Google News & Yahoo Finance
• Protara Therapeutics on LinkedIn, X (Twitter) & YouTube